| Date | Title | Description |
| 30.10.2024 | Future Investment Initiative (FII) Institute Day 1 - October 29, 2024 | The World's Visionary Leaders Address Humanity's Challenges
RIYADH, Saudi Arabia, Oct. 30, 2024 /PRNewswire/ -- The opening day of the 8th annual Future Investment Initiative (FII) kicked off at the King Abdulaziz International Conference C... |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 29.10.2024 | Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics | SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 29.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions | Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its ov... |
| 28.10.2024 | Agomab's $89 Million Boost: A Leap Towards Fibrosis Solutions | Agomab Therapeutics is on the rise. The Belgium-based biotech company recently secured $89 million in a Series D funding round. This infusion of capital comes from a mix of new and existing investors, including heavyweights like Sanofi and ... |
| 28.10.2024 | AbbVie to Acquire Aliada Therapeutics | AbbVie (NYSE: ABBV), Chicago, IL-based acquired Aliada Therapeutics, a Boston, MA-based biotechnology company focused on central nervous system (CNS) diseases.
AbbVie will acquire all outstanding Aliada equity for $1.4 Billion in cash, subj... |
| 28.10.2024 | Agomab: $89 Million (Series D) Raised For Supporting Broad Fibrosis-Focused Pipeline | Agomab Therapeutics announced a $89 million (€82.1 million) Series D funding round, with participation from new investors Sanofi and Invus, as well as existing investors.
The proceeds from this Series D funding round will be used to further... |
| 28.10.2024 | South Africa’s ‘Pick n Pay’ to exit Nigeria after selling 51% stake in its joint venture | South African grocery retailer Pick n Pay is set to exit the Nigerian market by selling its 51% stake in a joint venture, as part of a broader restructuring strategy outside its home market, CEO Sean Summers announced on Monday as reported ... |
| 25.10.2024 | Agomab Raises $89M in Series D Financing | Agomab Therapeutics, an Antwerp, Belgium-based biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases, raised $89M in Series D funding.
Backers included Sanofi and Invus.
Led by CEO ... |
| 24.10.2024 | Fortune Global Forum Speaker Lineup Unveiled for Nov. 11-12 in New York City | Seven-Time World Champion and Entrepreneur Tom Brady and Deputy Managing Director of the IMF Gita Gopinath among other luminaries confirmed to speak at Fortune's annual gathering of top global business executives and policy leaders
Leon Pan... |
| 24.10.2024 | Sobi Q3 2024 report: Strong growth and significant pipeline momentum | Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Thu, Oct 24, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024
Third Quarter 2024
• Total... |
| 23.10.2024 | Zantac Lawsuit Lawyer: What You Need to Know | Share
Tweet
Share
Share
Email
If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be entitled to legal compensation through a Zantac lawsuit. Due to increasing evidence linki... |
| 21.10.2024 | Sanofi reaches deal on terms of sale of consumer health arm, say French government sources | DealsHealthcare Providers
Employee Health
Sanofi reaches deal on terms of sale of consumer health arm, say French government sources
By ReutersOctober 20, 20249:31 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Li... |
| 21.10.2024 | Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare | Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talente... |
| 20.10.2024 | Tolerance Bio: Pioneering the Future of Immune Health with $17.2 Million Seed Funding | In the world of biopharmaceuticals, innovation is the lifeblood. Tolerance Bio, a Philadelphia-based company, has just secured $17.2 million in seed funding. This financial boost is not just a number; it represents a beacon of hope for many... |
| 20.10.2024 | Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting Function Of The Thymus | Tolerance Bio – a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the closing of its ... |
| 19.10.2024 | The Dawn of a New Era in Drug Discovery: Sanyou Bio's Super-Trillion Molecule Library | In the bustling heart of Shanghai, a revolution is brewing in the world of pharmaceuticals. Sanyou Bio, under the visionary leadership of Lang Guojun, has unveiled a groundbreaking innovation: the super-trillion molecule library. This monum... |
| 17.10.2024 | Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library | SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxiey... |
| 17.10.2024 | Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint | SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 17.10.2024 | Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines | Sanofi and Orano join forces to develop next-generation radioligand medicines
Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have enter... |
| 15.10.2024 | Sanofi: Information concerning the total number of voting rights and shares - September 2024 | Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financi... |
| 15.10.2024 | Wazoku powers One Big Thing: empowering UK civil servants to drive change | The UK Government has launched One Big Thing, an innovation programme that aims to inspire civil servants to make small, impactful changes that spark innovation across departments.
The programme runs until 14 February 2025 and will provide ... |
| 15.10.2024 | Oncovita Appoints Stéphane Altaba as CEO | Oncovita, a Paris, France-based biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, announced the appointment of Dr. Stéphane Altaba as its new Chief Executive Officer.
Stéphane Al... |
| 15.10.2024 | Glooko: Digital Health Company Raises $100 Million (Series F) | Glooko, a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, announced that it has secured a $100 million Series F funding round. And the company’s Board of Directors also announ... |
| 14.10.2024 | Scope3: Collaborative Sustainability Platform Company Raises $25 Million | Scope3, a collaborative sustainability platform decarbonizing media and advertising, announced the closing of $25 million in a strategic funding round led by GV. The funding round included participation from existing investors Venrock, Room... |
| 14.10.2024 | СD&R близка к покупке потребительского подразделения Sanofi за €15 млрд | Французская фармацевтическая компания Sanofi планирует выделить или продать свое потребительское подразделение, чтобы поддержать расходы на разработку новых лекарственных препаратов в рамках своего основного бизнеса.
В сентябре агентство Bl... |
| 11.10.2024 | Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella | Sanofi en discussions pour céder une participation majoritaire dans Opella
Paris, 11 octobre 2024. Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession potentielle d’une participation de contrôle de 50% d... |
| 11.10.2024 | Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella | Sanofi en discussions pour céder une participation majoritaire dans Opella
Paris, 11 octobre 2024. Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession potentielle d’une participation de contrôle de 50% d... |
| 11.10.2024 | Press Release: Sanofi in discussions to sell a controlling stake in Opella | Sanofi in discussions to sell a controlling stake in Opella
Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consum... |
| 11.10.2024 | Scope3 Raises $25M in Funding to Expand into Sustainable AI | Scope3, the collaborative sustainability platform decarbonizing media and advertising, announced the closing of $25 million in new funding led by GV. The round included participation from existing investors Venrock, Room40 Ventures, and Cra... |
| 11.10.2024 | Press Release: Sanofi in discussions to sell a controlling stake in Opella | Sanofi in discussions to sell a controlling stake in Opella
Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consum... |
| 10.10.2024 | The Double-Edged Sword of AI in Innovation and Security | Artificial Intelligence (AI) is a double-edged sword. On one side, it fuels innovation, sparking creativity and new ideas. On the other, it raises significant security concerns, especially in software development. Recent studies reveal a co... |
| 10.10.2024 | Scope3 Raises $25 Million in Funding to Expand into Sustainable AI | Scope3, the collaborative sustainability platform decarbonizing media and advertising, today announced the closing of $25 million in new funding led by GV. The round included participation from existing investors Venrock, Room40 Ventures, a... |
| 10.10.2024 | Glooko Secures $100M, Appoints Mike Alvarez as New CEO | – Glooko, a global digital health company, has announced a successful Series F funding round, raising $100M to fuel its continued growth and product development led by Georgian, with participation from Health Catalyst Capital, Canaan, and o... |
| 09.10.2024 | Tencent Partners with Pfizer to Launch Smart Healthcare Innovation Ecosystem - Zhang Yu Highlights "Dual-Engine" Strategy for Healthcare Digitization | HANGZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Tencent Health and Pfizer China have launched the "Pfizer Smart Healthcare Innovation Ecosystem" at the "Tides of Qiantang" Conference. This collaboration aims to drive innov... |
| 08.10.2024 | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 08.10.2024 | 85% of Global Innovators Using GenAI for Research and Learning | New study from Wazoku and King’s Business School reveals extent that AI is supporting and powering innovation and new ideas
Generative AI and Large Language Models (LLMs) are increasingly being used to drive global innovation, according to ... |
| 08.10.2024 | Investor duo launch new healthtech VC firm | Digital health investors David Buller and Laurent van Lerberghe have announced the launch of KELES. This new venture capital firm will focus on making digital health growth investments across Europe, with the aim of bridging the gap between... |
| 02.10.2024 | Owkin Partners with AstraZeneca for Advanced AI gBRCA Pre-Screening | Share
Tweet
Share
Share
Email
Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer.
Takeaway Points Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast canc... |
| 01.10.2024 | Innovent's Picankibart: A New Dawn for Psoriasis Treatment in China | In the ever-evolving landscape of biopharmaceuticals, Innovent Biologics has emerged as a beacon of hope for millions suffering from moderate to severe plaque psoriasis. The company recently announced that its New Drug Application (NDA) for... |
| 28.09.2024 | Commentary: What will it take to eliminate dengue deaths in Singapore? | Listen to this article
Commentary: What will it take to eliminate dengue deaths in Singapore?
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: Is a future with zero dengue deaths possible in Singa... |
| 27.09.2024 | Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD | Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent... |
| 27.09.2024 | Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD | Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
Following recent approvals in the EU and China, the U.S. approval... |
| 27.09.2024 | Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO | Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Cette approbation fait suite à celle obtenue dans l’Union européenne pour le traitement des adultes atteints de bronchopneumopathie chronique obstructiv... |
| 27.09.2024 | Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO | Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un phénotype éosinophilique. L... |
| 27.09.2024 | Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) | Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-r... |
| 27.09.2024 | Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD | Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent app... |
| 27.09.2024 | Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD | Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
Following recent approvals in the EU and China, the U.S. approval... |
| 27.09.2024 | Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD | Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent... |
| 27.09.2024 | Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) | Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-r... |
| 27.09.2024 | Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD | Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent app... |
| 26.09.2024 | Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis | SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 26.09.2024 | Press Release: Availability of the Q3 2024 Aide mémoire | Availability of the Q3 2024 Aide mémoire
Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website:
Third quarter 2024 results (sanofi.co... |
| 25.09.2024 | Synple chem joins US-based eMolecules |
Founded by Benedikt Wanner (Founder & CEO) AND Paula Nichols (Co-founder and CCO) along with their team, Synpl Chem is a pioneering Zurich-based company that specializes in automated chemical synthesis for small molecules drug discover... |
| 20.09.2024 | US FTC sues drug 'gatekeepers' over high insulin prices | Healthcare & PharmaceuticalsHealth
Health Insurance
Healthcare Providers
Litigation
US FTC sues drug 'gatekeepers' over high insulin prices
By Jody Godoy and Ahmed AbouleneinSeptember 20, 20248:06 PM UTCUpdated ago
Text
Small Text
Mediu... |
| 20.09.2024 | Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old | Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histol... |
| 20.09.2024 | Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old | Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents
If approved, Dupixen... |
| 20.09.2024 | Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study | Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhib... |
| 20.09.2024 | Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans... | Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Approval based on positive results from the IMROZ... |
| 20.09.2024 | Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans... | Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Approval based on positive results from the IMROZ... |
| 20.09.2024 | Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagno... | Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une transplantation
Approbation fondée ... |
| 19.09.2024 | Innovent Biologics: Pioneering New Frontiers in Cancer Treatment | In the world of oncology, the quest for effective treatments is relentless. Innovent Biologics, a biopharmaceutical company based in China, is at the forefront of this battle. Recently, they presented groundbreaking clinical data at the 202... |
| 18.09.2024 | Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 202... | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 18.09.2024 | Beijing E-Town’s Themed Exhibition Area Shines at the 2024 Beijing International Fair for Trade in Services | BEIJING, CHINA – Media OutReach Newswire – 18 September 2024 – On September 12, the 2024 China International Fair for Trade in Services officially kicked off. The Beijing Economic-Technological Development Area (also known as Beijing E-Town... |
| 18.09.2024 | Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 17.09.2024 | PulPac and PA Consulting unveil Dry Molded Fiber Cap now testing with the Bottle Collective | PulPac and PA Consulting unveil Dry Molded Fiber Cap now testing with the Bottle Collective
Tue, Sep 17, 2024 08:57 CET Report this content
The image shows generic Dry Molded Fiber bottles and the new bottle cap.
PulPac, the innovator behin... |
| 16.09.2024 | Sanofi: Information concerning the total number of voting rights and shares - August 2024 | Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financi... |
| 13.09.2024 | Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP
Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal po... |
| 13.09.2024 | Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP
Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal po... |
| 13.09.2024 | Rwandan startup Kasha raised additional funds to expand its digital healthcare services | In order to support its growth into more African nations, Rwandan startup Kasha, a digital platform for last-mile access to healthcare, has obtained equity funding from Sanofi Global Health Unit’s Impact Investment Fund.
Kasha, a digital re... |
| 12.09.2024 | Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 12.09.2024 | Moderna expects up to $3.5 billion in 2025 sales | Healthcare & PharmaceuticalsCommercial Strategy
Public Health
Moderna expects up to $3.5 billion in 2025 sales
By Patrick WingroveSeptember 12, 202410:15 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin... |
| 12.09.2024 | Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares | Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares
Paris (France) et Houston (Texas), le 12 septembre 2024. Dans le cadre d... |
| 12.09.2024 | Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people... |
| 11.09.2024 | Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU | Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatm... |
| 11.09.2024 | Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée | Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée Cette deuxième étude pivot menée chez des patients n’ayant jamais été t... |
| 11.09.2024 | Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial | Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant ste... |
| 11.09.2024 | Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) | Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compar... |
| 11.09.2024 | Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial | Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant ste... |
| 11.09.2024 | Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study | Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-seve... |
| 11.09.2024 | Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU | Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatm... |
| 11.09.2024 | Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) | Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compar... |
| 11.09.2024 | Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC | SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 11.09.2024 | Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study | Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-seve... |
| 11.09.2024 | Communiqué de presse : Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients... | Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients atteints de pemphigoïde bulleuse L’étude a satisfait aux critè... |
| 10.09.2024 | NanoSyrinx: A New Dawn in Biotech with £10 Million Funding | In the world of biotechnology, innovation is the lifeblood. Today, a new player is making waves. NanoSyrinx, a synthetic biology company based in Coventry, UK, has successfully raised approximately £10 million (around $13 million) in a rece... |
| 10.09.2024 | NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman | Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind
Appointment of Edwin Moses as Chairman to support the leadership team in ... |
| 10.09.2024 | Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône | Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône
Paris, le 10 septembre 2024. En présence du Président de la République, Emmanuel Macron, Sanofi a inauguré ce jour à Neuville-sur-Saône (... |
| 10.09.2024 | The invisible burden of type 1 diabetes through the eyes of a caregiver | (BPT) - Sponsored by Sanofi
Caregiving for those with type 1 diabetes is more than a responsibility, it’s a full-time job, requiring around-the-clock care and attention. From monitoring your loved one’s blood sugar, to managing food intake,... |
| 10.09.2024 | NanoSyrinx Closes Approx. £10M Financing | NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding.
The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing inves... |
| 10.09.2024 | Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation | SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 02.09.2024 | Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 02.09.2024 | CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des p... | Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant une sclérose en plaqu... |
| 29.08.2024 | Innovent and Lilly: Pioneering Paths in Biopharmaceuticals | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: Innovent Biologics and Eli Lilly. Both are making waves, each with a unique approach to tackling pressing health issues. Innovent, based in Suzhou, China, is car... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 29.08.2024 | Understanding the toll on adults diagnosed with type 1 diabetes; new survey findings | (BPT) - Sponsored by Sanofi
Every year, tens of thousands of Americans are newly diagnosed with type 1 diabetes, an autoimmune disease characterized by the immune system attacking insulin-producing cells in the pancreas.
For many, that diag... |
| 29.08.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024 | SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
